A Randomized Withdrawal, Placebo-Controlled Study Evaluating the Efficacy and Tolerability of Tapentadol Extended Release in Patients With Chronic Painful Diabetic Peripheral Neuropathy
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This study evaluated the efficacy and tolerability of tapentadol extended release (ER) for the management of chronic pain associated with diabetic peripheral neuropathy (DPN). RESEARCH DESIGN AND METHODS: Adults with moderate to severe DPN pain were titrated to tapentadol ER 100–250 mg bid during a 3-week open-label period; patients with ≥1-point reduction in pain intensity (11-point numerical rating scale) at end of titration were randomized to receive placebo or tapentadol ER (optimal dose from titration) for 12 weeks (double-blind, fixed-dose maintenance phase). The primary end point was mean change in average pain intensity from the start to week 12 (last observation carried forward [LOCF]) of the double-blind maintenance phase. RESULTS: A total of 358 patients completed the titration period; 318 patients (placebo, n = 152; tapentadol ER, n = 166) were randomized and received one or more doses of double-blind study medication. Mean (SD) pain intensity (observed case) was 7.33 (1.30) at the start and 4.16 (2.12) at week 3 of the open-label titration period (mean [SD] change, –3.22 [1.97]). The mean (SD) change in pain intensity (LOCF) from start of double-blind treatment to week 12 was as follows: placebo, 1.30 (2.43); tapentadol ER, 0.28 (2.04; least squares mean difference, –0.95 [95% CI –1.42 to –0.49]; P < 0.001). Treatment-emergent adverse events (≥10%) in the tapentadol ER group during the double-blind maintenance phase were nausea (21.1%) and vomiting (12.7%). CONCLUSIONS: Tapentadol ER (100–250 mg bid) was effective and well tolerated for the management of moderate to severe chronic pain associated with DPN.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EuroQol: the current state of play
Brooks, R. (1996) · Health Policy · doi:10.1016/0168-8510(96)00822-6 · Cited by 5,815 · cited 7×
“The changes from the start of open-label titration to doubleblind end point in BPI-SF scores and from the start of the double-blind period to double-blind end point in NPSI scores, SF-36 subscale and summary scales, and the EQ-5D health status index were evaluated using an ANCOVA model similar to that used for analysi…”
MethodInfluentialCore outcome measures for chronic pain clinical trials: IMMPACT recommendations
Dworkin, R. H., Turk, D. C., Farrar, J. T., Haythornthwaite, J. A., Jensen, M. P., Katz, N. P., Kerns, R. D., Stucki, G., Allen, R. R., Bellamy, N., et al. (2005) · Pain · doi:10.1016/j.pain.2004.09.012 · Cited by 3,732
Core outcome domains for chronic pain clinical trials: IMMPACT recommendations
Turk, D. C., Dworkin, R. H., Allen, R. R., Bellamy, N., Brandenburg, N., Carr, D. B., Cleeland, C., Dionne, R., Farrar, J. T., Galer, B. S., et al. (2003) · Pain · doi:10.1016/j.pain.2003.08.001 · Cited by 3,510
Dworkin, R. H., Turk, D. C., Wyrwich, K. W., Beaton, D., Cleeland, C. S., Farrar, J. T., Haythornthwaite, J. A., Jensen, M. P., Kerns, R. D., Ader, D. N., et al. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2007.09.005 · Cited by 3,471 · cited 10×
“The changes from the start of open-label titration to doubleblind end point in BPI-SF scores and from the start of the double-blind period to double-blind end point in NPSI scores, SF-36 subscale and summary scales, and the EQ-5D health status index were evaluated using an ANCOVA model similar to that used for analysi…”
MethodInfluentialSelf-citationECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896
The prevention and treatment of missing data in clinical trials
Little, R. J., D'Agostino, R., Cohen, M. L., Dickersin, K., Emerson, S. S., Farrar, J. T., Frangakis, C., Hogan, J. W., Molenberghs, G., Murphy, S. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmsr1203730 · Cited by 1,884
Mechanisms of neuropathic pain
Campbell, J. N., & Meyer, R. A. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.021 · Cited by 1,471
Development and validation of the Neuropathic Pain Symptom Inventory
Bouhassira, D., Attal, N., Fermanian, J., Alchaar, H., Gautron, M., Masquelier, E., Rostaing, S., Lanteri-Minet, M., Collin, E., Grisart, J., et al. (2004) · Pain · doi:10.1016/j.pain.2003.12.024 · Cited by 1,329
Bril, V., England, J., Franklin, G. M., Backonja, M., Cohen, J., Del Toro, D., Feldman, E., Iverson, D. J., Perkins, B., Russell, J. W., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e3182166ebe · Cited by 634
Handelsman, Y., Mechanick, J. I., Blonde, L., Grunberger, G., Bloomgarden, Z. T., Bray, G. A., Dagogo-Jack, S., Davidson, J. A., Einhorn, D., Ganda, O., et al. (2011) · Endocrine Practice · doi:10.4158/ep.17.s2.1 · Cited by 513 · cited 1×
“Thus, current treatment guidelines generally focus on the use of single agents (1,24,30), even though patients treated with a single agent often do not achieve satisfactory pain relief (3).”
BackgroundSelf-citationTesfaye, S., Vileikyte, L., Rayman, G., Sindrup, S. H., Perkins, B. A., Baconja, M., Vinik, A. I., Boulton, A. J. M., & Neuropathy, O. B. O. T. T. E. P. O. D. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1225 · Cited by 410
Self-citation
Research works printed but not linked: 22
- Vinik, 2010, The approach to the management of the patient with neuropathic pain, J Clin Endocrinol Metab, 95, 4802, 10.1210/jc.2010-0892 · DOI · Paper page
- Dworkin, 2010, Recommendations for the pharmacological management of neuropathic pain: an overview and literature update, Mayo Clin Proc, 85, S3, 10.4065/mcp.2009.0649 · DOI · Paper page
- Tzschentke, 2007, (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel μ-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties, J Pharmacol Exp Ther, 323, 265, 10.1124/jpet.107.126052 · DOI · Paper page
- Lee, 2010, A review of SSRIs and SNRIs in neuropathic pain, Expert Opin Pharmacother, 11, 2813, 10.1517/14656566.2010.507192 · DOI
- Trescot, 2008, Opioid pharmacology, Pain Physician, 11, S133, 10.36076/ppj.2008/11/S133 · DOI · Paper page
- Kroenke, 2009, Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews, Gen Hosp Psychiatry, 31, 206, 10.1016/j.genhosppsych.2008.12.006 · DOI · Paper page
- Schwartz, 2011, Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial, Curr Med Res Opin, 27, 151, 10.1185/03007995.2010.537589 · DOI · Paper page
- Afilalo, 2010, Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study, Clin Drug Investig, 30, 489, 10.2165/11533440-000000000-00000 · DOI · Paper page
- Buynak, 2010, Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study, Expert Opin Pharmacother, 11, 1787, 10.1517/14656566.2010.497720 · DOI · Paper page
- Wild, 2010, Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain, Pain Pract, 10, 416, 10.1111/j.1533-2500.2010.00397.x · DOI · Paper page
- Zannikos, 2013, Pharmacokinetic evaluation of tapentadol extended-release tablets in healthy subjects, J Opioid Manag, 9, 291, 10.5055/jom.2013.0171 · doi:10.5055/jom.2013.0171
- Cleeland, 1994, Pain assessment: global use of the Brief Pain Inventory, Ann Acad Med Singapore, 23, 129
- Crawford, 2008, Conceptual adequacy of the neuropathic pain symptom inventory in six countries, Health Qual Life Outcomes, 6, 62, 10.1186/1477-7525-6-62 · DOI
- Ware, 1993, SF-36 Health Survey Manual and Interpretation Guide
- Wesson, 2003, The Clinical Opiate Withdrawal Scale (COWS), J Psychoactive Drugs, 35, 253, 10.1080/02791072.2003.10400007 · DOI · Paper page
- Quessy, 2008, Placebo response in neuropathic pain trials, Pain, 138, 479, 10.1016/j.pain.2008.06.024 · DOI · Paper page
- Vinik, 2013, Relationship between pain relief and improvements in patient function/quality of life in patients with painful diabetic peripheral neuropathy or postherpetic neuralgia treated with pregabalin, Clin Ther, 35, 612, 10.1016/j.clinthera.2013.03.008 · DOI
- Bouhassira, 2008, Prevalence of chronic pain with neuropathic characteristics in the general population, Pain, 136, 380, 10.1016/j.pain.2007.08.013 · DOI · Paper page
- Argoff, 2006, Consensus guidelines: treatment planning and options. Diabetic peripheral neuropathic pain, Mayo Clin Proc, 81, S12, 10.1016/S0025-6196(11)61475-4 · DOI · Paper page
- American Society of Pain Educators, 2006, Diabetic peripheral neuropathic pain. Consensus guidelines for treatment, J Fam Pract, 2006, 1
- Gálvez, 2013, Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study, Adv Ther, 30, 229, 10.1007/s12325-013-0015-6 · DOI
- Steigerwald, 2012, Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study, Curr Med Res Opin, 28, 911, 10.1185/03007995.2012.679254 · DOI
Cited by
Diabetic neuropathy: A position statement by the American Diabetes Association
Pop-Busui, R., Boulton, A. J. M., Feldman, E. L., Bril, V., Freeman, R., Malik, R. A., Sosenko, J. M., & Ziegler, D. (2017) · Diabetes Care · doi:10.2337/dc16-2042 · Cited by 2,602
“Extended-release tapentadol was approved by the FDA for the treatment of neuropathic pain associated with diabetes based on data from two multicenter randomized withdrawal, placebocontrolledphase3 trials (103,104).”
BackgroundFeldman, E. L., Callaghan, B. C., Pop-Busui, R., Zochodne, D. W., Wright, D. E., Bennett, D. L., Bril, V., Russell, J. W., & Viswanathan, V. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0092-1 · Cited by 1,697
Opioids for Chronic Noncancer Pain: A Systematic Review and Meta-analysis
Busse, J. W., Wang, L., Kamaleldin, M., Craigie, S., Riva, J. J., Montoya, L., Mulla, S. M., Lopes, L. C., Vogel, N., Chen, E., et al. (2018) · JAMA · doi:10.1001/jama.2018.18472 · Cited by 716
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Self-citationHandelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Self-citation
Metadata
- Authors
- Vinik, A. I., Shapiro, D. Y., Rauschkolb, C., Lange, B., Karcher, K., Pennett, D., & Etropolski, M. S.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-07-12
- Volume
- 37
- Issue
- 8
- Pages
- 2302-2309
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W1980075122
- Cited by
- 132
- References
- 11
- FWCI
- 7.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.